We are live on
!
Find out more
BG
Bellevue Group Portfolio holdings
AUM
$4.2B
1-Year Est. Return
54.85%
This Fund
S&P 500
This Quarter
Est. Return
-10.66%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$551M
AUM Growth
–
Cap. Flow
+$550M
Cap. Flow
% of AUM
99.74%
Top 10 Holdings %
Top 10 Hldgs %
31.05%
Holding
130
New
130
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$21.7M |
| 2 |
Gilead Sciences
GILD
|
+$21M |
| 3 |
Medtronic
MDT
|
+$20.8M |
| 4 |
Biogen
BIIB
|
+$20.2M |
| 5 |
Amgen
AMGN
|
+$15.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93% |
| 2 | Financials | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cooper Companies
COO
$14B
| $3.62M | 0.66% |
+94,000
| New | +$3.25M |
|
|
IPXL
52
DELISTED
Impax Laboratories, Inc.
IPXL
| $3.46M | 0.63% |
+108,000
| New | +$3.8M |
|
53
Pfizer
PFE
$143B
| $3.26M | 0.59% |
+115,940
| New | +$3.31M |
|
|
ACHN
54
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.24M | 0.59% |
+420,000
| New | +$3.08M |
|
55
Community Health Systems
CYH
$465M
| $3.24M | 0.59% |
+211,556
| New | +$3.23M |
|
|
CERN
56
DELISTED
Cerner Corp
CERN
| $3.18M | 0.58% |
+60,000
| New | +$3.27M |
|
57
Merck
MRK
$315B
| $3.17M | 0.58% |
+62,880
| New | +$3.08M |
|
|
ARIA
58
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $3.16M | 0.57% |
+495,000
| New | +$2.77M |
|
|
MASI
59
DELISTED
Masimo
MASI
| $3.14M | 0.57% |
+75,000
| New | +$2.82M |
|
60
Halozyme
HALO
$9.23B
| $3.01M | 0.55% |
+318,000
| New | +$2.99M |
|
|
NVDQ
61
DELISTED
Novadaq Technologies Inc.
NVDQ
| $2.99M | 0.54% |
+270,000
| New | +$2.86M |
|
62
Nektar Therapeutics
NKTR
$2.31B
| $2.97M | 0.54% |
+14,400
| New | +$2.77M |
|
|
VAR
63
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.96M | 0.54% |
+42,194
| New | +$2.87M |
|
64
Cencora
COR
$59.9B
| $2.94M | 0.53% |
+34,000
| New | +$3.03M |
|
|
NUVA
65
DELISTED
NuVasive, Inc.
NUVA
| $2.92M | 0.53% |
+60,000
| New | +$2.72M |
|
|
MDVN
66
DELISTED
MEDIVATION, INC.
MDVN
| $2.9M | 0.53% |
+63,000
| New | +$2.29M |
|
67
Thermo Fisher Scientific
TMO
$198B
| $2.83M | 0.51% |
+20,000
| New | +$2.68M |
|
|
HOLX
68
DELISTED
Hologic
HOLX
| $2.79M | 0.51% |
+81,000
| New | +$2.82M |
|
69
Neurocrine Biosciences
NBIX
$17.2B
| $2.57M | 0.47% |
+65,000
| New | +$2.58M |
|
70
Eli Lilly
LLY
$1.05T
| $2.52M | 0.46% |
+35,000
| New | +$2.65M |
|
|
SGEN
71
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.39M | 0.43% |
+68,000
| New | +$2.28M |
|
72
United Therapeutics
UTHR
$22.7B
| $2.33M | 0.42% |
+19,300
| New | +$2.44M |
|
73
Inovio Pharmaceuticals
INO
$92.1M
| $2.31M | 0.42% |
+22,083
| New | +$1.7M |
|
74
Alkermes
ALKS
$8.79B
| $2.24M | 0.41% |
+65,500
| New | +$2.59M |
|
75
Agios Pharmaceuticals
AGIO
$2.36B
| $2.19M | 0.4% |
+54,000
| New | +$2.31M |
|
Similar funds
WSFS
AC
HIP
DT
ATPW
BT
NCM
MSU
Bellevue Group's Q1 2016 Portfolio in Review
Q1 2016 is the first quarter with a 13F filing on record for Bellevue Group, which disclosed 130 positions worth $551M. Its ten largest holdings account for 31% of the portfolio.
Its largest position is Celgene Corp: 210,550 shares worth $21.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Financials.
- Bellevue Group's largest Q1 2016 buy was Celgene Corp: 210,550 shares worth $21.1M.
- Bellevue Group's ten largest holdings make up 31% of its $551M portfolio in Q1 2016.
- Bellevue Group disclosed 130 positions in Q1 2016, its first 13F filing on record.
Based on Bellevue Group's 13F filing for Q1 2016, filed 16 May 2016.